The development of molecularly targeted drugs has greatly advanced cancer therapy, despite these drugs being associated with some serious problems. Recently, increasing attention has been paid to the anticancer effects of natural products. α-Mangostin, a xanthone isolated from the pericarp of mangosteen fruit, has been shown to induce apoptosis in various cancer cell lines and to exhibit antitumor activity in a mouse mammary cancer model. In this study, we investigated the influence of α-mangostin on apoptosis and cell cycle in the human breast cancer cell line MDA-MB231 (carrying a p53 mutation, and HER2, ER, and PgR negative) in order to elucidate its anticancer mechanisms. In α-mangostin-treated cells, induction of mitochondria-mediated apoptosis was observed. On cell-cycle analysis, G1-phase arrest, increased p21 cip1 expression and decreases in cyclins, cdc(s), CDKs and PCNA were observed. In conclusion, α-mangostin may be useful as a therapeutic agent for breast cancer carrying a p53 mutation and having HER2-and hormone receptor-negative subtypes.
Introduction
Various molecularly targeted drugs against a range of cancers, including breast cancer, have recently been developed. Trastuzumab is a monoclonal antibody against human epidermal growth factor (HER/ErbB) receptor 2 (HER2/ErbB2). Around 15-20% of patients with breast cancer have HER2-positive tumors, and overexpression of HER2 is observed in these patients [1] . Trastuzumab has been shown to induce tumor regression in such patients. Sunitinib, sorafenib, and bevacizumab are multitargeted tyrosine kinase inhibitors that inhibit tumor neovascularization and are currently in clinical trials [2, 3] . These drugs are associated with serious problems such as adverse effects, drug resistance, and low efficacy of single therapy, particularly against metastatic or recurrent breast cancer. Hormone therapy has also been used against hormone receptor-positive breast cancer. However, about 10 to 15% of breast cancers do not express either estrogen or progesterone receptor (ER and PgR, resp.) and do not overexpress the HER2 gene [4] .
Mangosteen (Garcinia mangostana Linn) pericarp contains various phytochemicals, primarily xanthones, and the resin extracts have long been used for medicinal purposes in Southeast Asia [5] . α-Mangostin is a one of xanthones present in mangosteen pericarp (78% content). A recent study has shown that α-mangostin induces cell-cycle arrest and apoptosis in various types of human cancer cells [5] [6] [7] [8] . We previously reported that α-mangostin significantly inhibits both tumor growth and metastasis in a mouse model of mammary cancer [9, 10] . In addition, α-mangostin treatment significantly decreased the levels of phospho-Aktthreonine 308(Thr308) in a human mammary carcinoma cell line and mammary carcinoma tissues in vivo [10] .
Journal of Biomedicine and Biotechnology
Here, we investigated the antitumor potential of α-mangostin on apoptosis and cell cycle arrest in a human breast cancer cell line carrying a p53 mutation and having HER2-, ER-, and PgR-negative status.
Materials and Methods

Experimental Regimen.
Mangosteen (Garcinia mangostana Linn) pericarps were dried, ground, and successively extracted in water and 50% ethanol. After freeze-drying the 50% ethanol extract, the resultant dried powder was suspended in water partitioned with ethyl acetate. The ethyl acetate extract was then purified by chromatography on silica gel with the n-hexane-ethyl acetate system and recrystallized to give α-mangostin at >98% purity. For in vitro use, crystallized α-mangostin was dissolved in dimethyl sulphoxide (DMSO), and aliquots of stock 20 mM solution were stored at −20
• C.
Cell Line.
The MDA-MB231, a human mammary carcinoma cell line stably expressing the green fluorescence protein (GFP) [11] , was maintained in RPMI-1640 medium containing 10% fetal bovine serum with streptomycin/penicillin in an incubator under 5% CO 2 . MDA-MB231 cells have a p53 mutation [12, 13] and HER2-, ER-, and PgR, negative feature [14] .
Cell Viability.
MDA-MB231 cells were grown in RPMI-1640 medium supplemented with 10% bovine serum under an atmosphere of 95% air and 5% CO 2 at 37 • C. These cells were plated into 96-well plates (1 × 10 4 cells/well) one day before α-mangostin treatment. They were subsequently incubated for 24 h with culture medium containing DMSO vehicle alone (control) or with medium containing α-mangostin at various concentrations up to 48 μM. Cell viability was determined using a Cell-Titer-Bule Cell Viability Assay (Promega Co., Madison, WI, USA). The IC 50 under these conditions was found to be 20 μM α-mangostin for 24 h treated and 16 μM for 48 h treated in MDA-MB231 cells; thus, all in vitro studies were performed using 20 μM α-mangostin.
Time-Lapse
Imaging. Cells were grown on 35 mm culture dishes under the above-mentioned condition. These cells were subsequently incubated for 24 h with culture medium containing DMSO vehicle alone (control) or with medium containing 20 μM α-mangostin. Imaging has started when the reagents were added into dishes. Time-lapse images were taken using the fluorescence microscope BZ8000 (Keyence, Osaka, Japan). Ltd., Ibaraki, Japan).
Nuclear
Cytochrome c Release.
Cytochrome c leaving the mitochondrial membrane was measured using the InnoCyte Flow Cytometric Cytochrome c Release Kit (Merck; Darmstadt, Germany). MDA-MB231 cells were harvested after a 24 h treatment with 20 μM α-mangostin or DMSO alone and 1 × 10 6 cells were resuspended in 300 μL Permeabilization Buffer to remove the cytosolic cytochrome c. The cells were fixed 4% paraformaldehyde and washed. After treatment with blocking buffer, the cells were treated with anticytochrome c mouse monoclonal antibody (clone 7H8, Santa Cruz, Biotechnology, CA, USA), followed by secondary antibody conjugated to FITC. Then, the cells were analyzed using a flow cytometer, BD FACSAria (Becton Dickinson, Franklin Lakes, NJ, USA). GE Healthcare UK Ltd., Buckinghamshire, UK). Blots were visualized using a LAS-3000 image analyzer (Fujifilm, Co., Tokyo, Japan).
Real-Time PCR.
MDA-MB231 cells were treated with DMSO or 20 μM α-mangostin for 6, 12, and 24 h. Protein was extracted using cell lysis buffer containing protease and phosphatase inhibitor cocktail. Total RNA was extracted from these cells with FastPure RNA kit (Takara Bio Inc., Shiga, Japan) and cDNAs were synthesized with PrimeScript RT reagent kit (Takara Bio Inc.). Primers involved in the cell-cycle regulation were used containing PrimerArray Cell cycle (human) (Takara Bio Inc.) and real-time PCR reaction was performed with Thermal Cycler Dice Real Time (Takara Bio Inc.). Data were corrected against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) values and expressed as mean ± SD.
Statistical
Analysis. Significant differences in the quantitative data between groups were analyzed using Student's ttest via the method of Welch, and P values less than 0.05 were considered to represent a statistically significant difference. after 24 and 48 h of treatment with more than 12 μM α-mangostin (Figure 1(a) ). Based on the IC 50 data, 20 μM was determined to be the optimal concentration of α-mangostin for in vitro studies.
Results and Discussion
Morphological Changes.
For morphological examination of apoptotic changes, MDA-MB231 cells were stained with Hoechst 33342 (Figure 1(b) ). After 20 μM α-mangostin treatment for 24 h, cells appeared shrunken and chromatin condensation was observed (yellow arrow heads in lower right panel). These changes suggest that the antiproliferative effects of α-mangostin are associated with apoptosis in MDA-MB231 human mammary cancer cells. Furthermore, we performed time-lapse imaging from the start of 20 μM α-mangostin treatment for 24 h. After 6 h, cell proliferation started to decrease significantly and cell shape had changed after 12 h (data not shown).
Apoptosis Studies
3.3.1. ssDNA Analysis. In order to confirm that the morphological changes observed after α-mangostin treatment occurred as a consequence of apoptosis, we measured ssDNA levels of α-mangostin treated cells, as compared to controls. In α-mangostin-treated cells, ssDNA levels were significantly elevated (P < 0.001, Figure 1(c) ). This suggests that the
6 h 12 h * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Relative levels of target gene expression were calculated using the ΔΔ CT method. GAPDH was used as a reference gene. Data are presented as means ± SD of triplicate independent measurements. morphological changes in human mammary cancer cells that occurred after α-mangostin treatment were caused by apoptosis.
Caspase Activity.
Significantly elevated caspase-3, caspase-8, and caspase-9 activity was observed in MDA-MB231 cells treated with α-mangostin for 24 h (Figure 2) , as compared to controls. The activity of caspase-4 did not differ significantly between control cells and α-mangostin-treated cells (Figure 2) . These results indicate that α-mangostininduced mitochondria mediated apoptosis.
Cytochrome c Release.
In order to confirm mitochondria-mediated apoptosis, levels of cytochrome c were measured by flow cytometry and Western blot. The levels of cytochrome c protein in mitochondrial fractions were significantly lower in cells treated with α-mangostin for 24 h (Figure 3(a) ). Cytochrome c protein was released from mitochondria, leading to decreases in concentration (Figure 3(b) ). These results were strongly suggesting engagement of the mitochondria-mediated apoptotic pathway.
Bid Cleavage.
As caspase-8 activity was elevated, we examined whether the mitochondrial pathway was activated via caspase-8-Bid cleavage by performing Western blots for Bid. Full-length Bid (22 kDa) was equally detected in control cells and in cells treated with α-mangostin for 24 h (Figure 3(c) ); this indicates that no Bid cleavage occurred. In addition, no cleaved Bid (15 kDa) was observed when using cleaved Bid-detectable antibody in any of the groups (data not shown). These results suggest that apoptosis was induced by α-mangostin via mitochondria, but was not accompanied by Bid cleavage. We previously reported that α-mangostin decreased phospho-Akt-Th308 in MDA-MB231 cells and mammary carcinoma tissues [10] . Akt is a serine/threonine protein kinase that mediates the downstream effects of phosphatidylinositol 3-kinase (PI3K) by phosphorylating multiple targets involved in regulating diverse cellular functions, including proliferation, growth, and survival. Therefore, Akt phosphorylation by therapeutic agents leads to growth inhibition, cell-cycle arrest, and apoptosis in cancer cells. A previous study in human colon cancer cells showed that α-mangostin inhibited Erk1/2 , and p21 cip1 (c), were examined using real-time PCR assays in MDA-MB231 cells after treatment with α-mangostin, as compared to controls. White bars indicate the results for controls and black bars indicate the results of analysis at 6 h, 12 h, and 24 h after treatment with α-mangostin ( * P < 0.05, * * P < 0.01). PCNA and cyclin D1 expressions were significantly lower and p21 cip1 was significantly higher in cells treated with α-mangostin for 24 h, as compared to controls. Relative target gene levels were calculated using the ΔΔCT method. GAPDH was used as a reference gene. Data are presented as means ± SD of triplicate independent measurements. (d) Western blots of PCNA (36 kDa) and cyclin D1 (36 kDa) showed significantly lower levels, and p21 cip1 (21 kDa) showed significantly higher levels in cells treated with α-mangostin for 24 h, as compared to controls (left lane). These results were similar to those for PCR analysis, as shown in (a)-(c). β-Actin served as an internal control (lowest panel). Three samples from control and α-mangostin-treated cells were used for measurement.
and Erk5 phosphorylation involving the mitogen-activated protein kinase (MAPK) signaling pathway [5] . PI3K/Akt and Erk signaling target Bcl-2-associated agonists of cell death (Bad), a member of the Bcl-2 family. Bcl-2 family members are known to be regulators of programmed cell death. Bad promotes apoptosis by displacing Bax, another Bcl-2 family member, from binding to Bcl-2 and Bcl-xL, causing cytochrome c release from mitochondria [15] . These data suggest that apoptotic cell death caused by α-mangostin treatment in human mammary carcinoma cells occurs via mitochondria-mediated apoptosis, followed by inhibition of PI3K/Akt signaling pathway, and may include Bad activation.
Cell-Cycle Distribution.
As measured by flow cytometry, 24 h exposure to 20 μM α-mangostin induced a significant elevation in the number of cells in the G1-phase, as compared with control cells (Figure 3(d) ). There was also a significant reduction in the S-phase population in α-mangostin-treated cells (Figure 3(d) ). These results suggest that G1-phase arrest was the result of α-mangostin inhibiting entry into S-phase.
Expression of Cell-Cycle Regulatory Genes.
As α-mangostin treatment induced cell-cycle arrest, we investigated the expression of cell-cycle regulatory genes. Real-time analysis revealed that the expression of p21 cip1 was up-regulated and CHEK2 expression tended to increase for more than 6 h after α-mangostin treatment (Figure 4) . p21 cip1 is a cyclindependent kinase inhibitor and the encoded protein binds to and inhibits the activity of cyclin-CDK2 (CDK: cyclindependent kinase) or -CDK4 complexes, thereby functioning as a regulator of cell-cycle progression at the G1-phase [16] . CHEK2 is one of the cell-cycle checkpoint regulators and putative tumor suppressors that lead to G1-phase arrest through CDK phosphatase and cell division cycle 25 homolog A (cdc25A) phosphorylation [17] . Increases in p21 cip1 and CHEK2 expression lead to decreases in CDKs and cyclins, and G1-phase arrest and inhibition of cell proliferation, followed by decreases in proliferating cell nuclear antigen (PCNA). Furthermore, we confirmed the expression of G1/S-phase-related molecules, particularly p21 cip1 , PCNA, and cyclin D1 by using Western blotting and immunofluorescence staining (Figures 5 and 6 ). On Western blotting analysis, PCNA (36 kDa) and cyclin D1 (36 kDa) protein were significantly lower, and p21 cip1 (21 kDa) protein was significantly elevated in cells treated with α-mangostin for 24 h, as compared to controls ( Figure 5(d) ). These results agreed with those of the real-time PCR analysis shown in Figures 4 and 5(a)-5(c) . Immunofluorescence staining revealed that PCNA and cyclin D1 expression were lower and that p21 cip1 expression was elevated in the nuclei of α-mangostin-treated cells, as compared to controls ( Figure 6 ). These results suggest that α-mangostin induces G1-phase arrest and S-phase suppression by altering the expression of cell-cycle-related molecules, such as p21 cip1 , CHEK2, cyclins, cdc(s), CDKs, and PCNA.
Conclusion
In conclusion, our results demonstrated that the therapeutic effects of α-mangostin are mediated by mitochondriamediated apoptosis under control of the PI3K/Akt signaling pathway. α-Mangostin may be useful as a therapeutic agent for breast cancer carrying a p53 mutation and including HER2/hormone-negative subtypes.
